Evidence of such a mechanism for TILs in ovarian carcinoma is still sparse (Raspollini et al, 2005; Yang et al, 2007), especially as the rate of HER2/neu-expressing tumour cells varies from 1.9 to 35% (Press et al, 2005). This evidence concerns the gene ERBB2 and ovarian carcinoma.